LU90011I2 - Remifentanil facultativement sous la forme d'un sel d'addition d'acide pharmaceutiquement acceptable y compris le chlorhydrate de remifentanil - Google Patents

Remifentanil facultativement sous la forme d'un sel d'addition d'acide pharmaceutiquement acceptable y compris le chlorhydrate de remifentanil

Info

Publication number
LU90011I2
LU90011I2 LU90011C LU90011C LU90011I2 LU 90011 I2 LU90011 I2 LU 90011I2 LU 90011 C LU90011 C LU 90011C LU 90011 C LU90011 C LU 90011C LU 90011 I2 LU90011 I2 LU 90011I2
Authority
LU
Luxembourg
Prior art keywords
lower alkyl
group
alkoxy
remifentanil
member selected
Prior art date
Application number
LU90011C
Other languages
English (en)
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of LU90011I2 publication Critical patent/LU90011I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LU90011C 1989-02-15 1997-01-24 Remifentanil facultativement sous la forme d'un sel d'addition d'acide pharmaceutiquement acceptable y compris le chlorhydrate de remifentanil LU90011I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31131189A 1989-02-15 1989-02-15
US07/448,497 US5019583A (en) 1989-02-15 1989-12-11 N-phenyl-N-(4-piperidinyl)amides useful as analgesics

Publications (1)

Publication Number Publication Date
LU90011I2 true LU90011I2 (fr) 1997-03-11

Family

ID=26977841

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90011C LU90011I2 (fr) 1989-02-15 1997-01-24 Remifentanil facultativement sous la forme d'un sel d'addition d'acide pharmaceutiquement acceptable y compris le chlorhydrate de remifentanil

Country Status (22)

Country Link
US (1) US5019583A (fr)
EP (1) EP0383579B1 (fr)
JP (1) JP2895145B2 (fr)
KR (1) KR0160979B1 (fr)
AT (1) ATE140451T1 (fr)
AU (1) AU636330B2 (fr)
CA (1) CA2010011C (fr)
CY (1) CY2002A (fr)
CZ (1) CZ402591A3 (fr)
DE (2) DE19675028I2 (fr)
DK (1) DK0383579T3 (fr)
ES (1) ES2088961T4 (fr)
GR (1) GR3020719T3 (fr)
HK (1) HK78297A (fr)
IE (1) IE77156B1 (fr)
LU (1) LU90011I2 (fr)
MX (1) MX9203024A (fr)
NL (1) NL960030I2 (fr)
NZ (1) NZ232542A (fr)
PT (1) PT93137B (fr)
SG (1) SG47967A1 (fr)
SK (1) SK402591A3 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214148A (en) * 1990-12-18 1993-05-25 Glaxo Inc. Analgesic N-phenyl-N-(3-OR1 -3-ME-4-piperidinyl)amides
US5130321A (en) * 1990-12-18 1992-07-14 Glaxo Inc. Analgesic n-phenyl-n-(3-or 1-3-me-4-piperidinyl)amides
GB9316863D0 (en) * 1993-08-13 1993-09-29 Glaxo Group Ltd Chemical process
US5466700A (en) * 1993-08-30 1995-11-14 Glaxo Wellcome Inc. Anesthetic use of N-phenyl-N-(4-piperidinyl)amides
US5866591A (en) * 1996-09-11 1999-02-02 Glaxo Wellcome Inc. Stable formulations of remifentanil
DE69831876T2 (de) * 1997-12-24 2006-07-27 Ortho-Mcneil Pharmaceutical, Inc. (4)-[aryl(piperidin-4-yl) aminobenzamidderivate die an delta-opioid rezeptor binden
US6858018B1 (en) * 1998-09-28 2005-02-22 Vyteris, Inc. Iontophoretic devices
US6436959B1 (en) 1998-12-23 2002-08-20 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)]aminobenzamides
JP2003515588A (ja) 1999-12-06 2003-05-07 マリンクロッド・インコーポレイテッド アルフェンタニル、スフェンタニルおよびレミフェンタニルの新合成法
WO2001068604A2 (fr) 2000-03-14 2001-09-20 Sepracor, Inc. Piperidines 3-substituees comprenant un groupement uree et procedes d'utilisation de ces dernieres
DK1307194T4 (da) 2000-07-31 2011-07-18 Nycomed Danmark Aps Fentanylpræparat til nasal administration
CA2443350A1 (fr) 2001-04-03 2002-12-05 Aryx Therapeutics Opioides a action ultrabreve pour application transdermique
JP2005516926A (ja) * 2001-12-17 2005-06-09 アリックス セラピューティクス 鎮痛薬の送達システム及び使用方法
WO2005030722A1 (fr) * 2003-09-29 2005-04-07 Nippon Chemiphar Co., Ltd. Derive d'amide de n-(4-piperidinyle) n-substitue
WO2005123679A2 (fr) * 2004-06-18 2005-12-29 Neurosearch A/S Nouveaux derives de piperidine substitues par alkyle et leur utilisation comme inhibiteurs de recaptage de neurotransmetteur de monoamine
EP1795526A4 (fr) * 2004-09-14 2010-10-13 Nippon Chemiphar Co Derive d amide n-(4-piperidinyl) n-substitue
EP1966140A1 (fr) * 2005-11-17 2008-09-10 Mallinckrodt, Inc. Procede de synthetisation du remifentanil
CN101374812A (zh) * 2006-01-24 2009-02-25 马林克罗特公司 合成瑞芬太尼的方法
JP2009525329A (ja) * 2006-02-03 2009-07-09 マリンクロッド・インコーポレイテッド レミフェンタニル塩酸塩の結晶形
EP1867635A1 (fr) * 2006-06-15 2007-12-19 Kern Pharma, S.L. Procédé de préparation de remifentanil, ses produits intermédiaires, leur application et procédé pour leur préparation
KR20170091770A (ko) * 2006-07-10 2017-08-09 파이온 유케이 리미티드 속효형 벤조디아제핀 염 및 이의 중합체 형태
GB0613693D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts (3)
US20100099880A1 (en) * 2006-10-05 2010-04-22 Brian Cheng Alternate Process for Remifentanil Preparation
US20100048908A1 (en) * 2006-11-29 2010-02-25 Brian Kai-Ming Cheng Process for Remifentanil Synthesis
JP5580287B2 (ja) * 2008-03-31 2014-08-27 ザ ジェネラル ホスピタル コーポレイション 改善された薬物速度論的および薬力学的特性を有するエトミデート類似体
US20110144346A1 (en) * 2008-07-03 2011-06-16 Cilag Ag Method for producing n-phenyl-n-(4-piperidinyl) amide salts
WO2010053944A1 (fr) * 2008-11-04 2010-05-14 Cambrex Charles City, Inc. Procédé amélioré de fabrication de dérivés de la pipéridine
CA2767112C (fr) 2009-07-10 2018-06-19 The General Hospital Corporation Analogues de l'etomidate qui n'inhibent pas la synthese de steroides corticosurrenaux
EP2450039A1 (fr) 2010-11-08 2012-05-09 PAION UK Ltd. Régime de dosage permettant la sédation avec CNS 7056 (Remimazolam)
ES2617536T3 (es) 2012-01-13 2017-06-19 The General Hospital Corporation Compuestos anestésicos y métodos relacionados de uso
JP6309957B2 (ja) 2012-10-08 2018-04-11 オークランド ユニサービシーズ リミティド ケタミン誘導体
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
CN103728403B (zh) * 2013-08-30 2015-10-07 宜昌人福药业有限责任公司 一种盐酸瑞芬太尼原料药中有关物质的检测方法
ES2699636T3 (es) 2016-01-29 2019-02-12 Bioka S R O Nuevo procedimiento para la preparación de derivados de N-fenil-N-(4-piperidinil) amida, como remifentanilo y carfentanilo
SI3643704T1 (sl) 2018-10-26 2021-04-30 Hameln Pharma Gmbh Novi intermediati za pripravo remifentanil hidroklorida
GB202010168D0 (en) 2020-07-02 2020-08-19 Johnson Matthey Plc Process for preparing remifentanil hydrochloride
CN114262320A (zh) * 2021-12-28 2022-04-01 宜昌人福药业有限责任公司 一种利用连续流微通道反应器制备苯胺基哌啶类药物的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE623427A (fr) * 1961-10-10
US3655675A (en) * 1968-09-09 1972-04-11 Sterling Drug Inc N-(n-heteryl)-acylanilides
US3998834A (en) * 1975-03-14 1976-12-21 Janssen Pharmaceutica N.V. N-(4-piperidinyl)-n-phenylamides and -carbamates
US4179569A (en) * 1975-03-14 1979-12-18 Janssen Pharmaceutica N.V. N-(4-piperidinyl)-N-phenylamides
US4167574A (en) * 1978-03-13 1979-09-11 Janssen Pharmaceutica, N.V. N-phenyl-N-(4-piperidinyl)amides
US4584303A (en) * 1984-04-09 1986-04-22 The Boc Group, Inc. N-aryl-N-(4-piperidinyl)amides and pharmaceutical compositions and method employing such compounds
US4801721A (en) * 1984-08-16 1989-01-31 Ryan James W Stereospecific synthesis of carboxyalkyl peptides
CA1317940C (fr) * 1987-09-25 1993-05-18 Georges H. P. Van Daele N-(1-alkyl-3-hydroxy-4-piperidinyl) benzamides a substituant

Also Published As

Publication number Publication date
CA2010011A1 (fr) 1990-08-15
IE77156B1 (en) 1997-12-03
AU636330B2 (en) 1993-04-29
AU4973190A (en) 1990-08-23
CY2002A (en) 1997-12-05
HK78297A (en) 1997-06-20
KR900012906A (ko) 1990-09-03
GR3020719T3 (en) 1996-11-30
DK0383579T3 (da) 1996-10-14
ES2088961T3 (es) 1996-10-01
NL960030I2 (nl) 1997-05-01
MX9203024A (es) 1992-07-01
CZ402591A3 (en) 1993-04-14
JP2895145B2 (ja) 1999-05-24
KR0160979B1 (ko) 1998-12-01
CA2010011C (fr) 1997-12-02
NZ232542A (en) 1992-06-25
US5019583A (en) 1991-05-28
PT93137A (pt) 1990-08-31
NL960030I1 (nl) 1997-02-03
EP0383579B1 (fr) 1996-07-17
ES2088961T4 (es) 1996-12-01
PT93137B (pt) 1996-02-29
IE900532L (en) 1990-08-15
DE69027794D1 (de) 1996-08-22
EP0383579A1 (fr) 1990-08-22
DE19675028I2 (de) 2002-11-07
SK402591A3 (en) 2000-09-12
ATE140451T1 (de) 1996-08-15
SG47967A1 (en) 1998-04-17
DE69027794T2 (de) 1997-01-02
JPH02300167A (ja) 1990-12-12

Similar Documents

Publication Publication Date Title
LU90011I2 (fr) Remifentanil facultativement sous la forme d'un sel d'addition d'acide pharmaceutiquement acceptable y compris le chlorhydrate de remifentanil
SE0104334D0 (sv) Therapeutic agents
ATE33835T1 (de) Verbindung mit antibronchopneumopathischer wirkung, verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen.
MX11031A (es) Proceso para la preparacion de nuevas 1-fenil-3-naftaleniloxipropanaminas producto obtenido y composicion farmaceutica que lo incluye.
KR960037675A (ko) 벤조니트릴 및 벤조플루오라이드
MA27197A1 (fr) Sels de tolterodine
FI860878A0 (fi) Aminosyraderivat och foerfarande foer deras framstaellning.
DK26289D0 (da) Anvendelse af 1,4-disubstitueret piperidinyl til fremstilling af et farmaceutisk praeparat til behandling af insomnia
PT90725A (pt) Processo para a preparacao de novos compostos cefem
MA27492A1 (fr) Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
ES2083737T3 (es) 4-((2-benzotiazolil)metilamino)-alfa-((3,4-difluorofenoxi)metil)-1-piperidina-etanol.
KR20210121989A (ko) 베타코로나바이러스 감염을 예방하기 위한 조성물
ATE86117T1 (de) Zusammensetzung gegen leberkrankheiten.
JPS5585550A (en) 4-homoisotwistane amino acid amide
TH20641A (th) 6-[ไทรแอโซลิล[3-(ไทรฟลูออโรเมธิล)เฟนิล]เมธิล]-2-ควิโนลิโนนและ-ควิโนลีนไธโอน
SE9904416D0 (sv) Crystalline form
DK0420464T3 (da) 3-isoxazolonderivater, deres fremstilling af deres terapeutiske anvendelser